E. Grandini
University of Bologna
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Grandini.
Journal of Clinical Virology | 2013
E. Loggi; C. Cursaro; A. Scuteri; E. Grandini; Arianna Martello Panno; Silvia Galli; Giuliano Furlini; Mauro Bernardi; Claudio Galli; Pietro Andreone
BACKGROUND An early drop of HCV-RNA levels is useful in assessing response to antiviral treatment in chronic hepatitis C; the first recommended time point is 4 weeks after the start of therapy. OBJECTIVES We evaluated retrospectively HCV-RNA and HCVAg levels at different time points to assess the clinical value of an early monitoring. STUDY DESIGN Thirty-five patients with chronic hepatitis C infected by genotype 1b and consecutively enrolled in an open-label study on PegIFN plus Ribavirin and/or ketoprofene were tested for HCV-RNA (real-time PCR) and HCVAg (ARCHITECT) at baseline and after 1 and 2 days and 1, 2, 4 and 12 weeks after the start of treatment. Treatment response was assessed according to the EASL consensus criteria. RESULTS In the 17 sustained responders (SR) the median log decrease of HCV-RNA and HCVAg at the different time points was 0.40 and 0.37; 1.36 and 0.84; 1.47 and 0.97; 2.34 and 1.86; 2.51 and 2.32; 3.28 and 2.61, respectively. The best time point to predict SR was 2 weeks after the start of therapy, with a sensitivity, specificity and overall accuracy of 76.9%, 86.7% and 82.1% for HCV-RNA and 81.8%, 75.0% and 76.8% for HCVAg, respectively. DISCUSSION An early monitoring is at least equally effective than standard monitoring in predicting response to hepatitis C therapy. The similarity of HCV-RNA and HCVAg kinetics suggests that HCVAg may be useful in the early phases as a trigger to evaluate HCV-RNA levels at earlier time points for a personalized approach to therapy monitoring.
Journal of Clinical Virology | 2017
E. Loggi; Stefano Gitto; Silvia Galli; Mario Minichiello; F. Conti; E. Grandini; A. Scuteri; Giovanni Vitale; Roberto Di Donato; C. Cursaro; Giuliano Furlini; Pietro Andreone
BACKGROUND Hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients treated with IFN-free direct acting antiviral (DAA) therapies has recently emerged as a potential risk. Given the potential burden of this issue, further data are needed to establish its actual clinical impact. OBJECTIVES The aim of the present study was to analyze the occurrence of HBV reactivation in a cohort of CHC patient treated with DAAs in routine clinical practice. STUDY DESIGN Consecutive CHC patients with different genotypes, treated with DAA between January 2015 and January 2016 were included in the study. Subjects had been tested for HBsAg and anti-HBc antibodies before antiviral therapy. HBV-DNA levels were examined in anti-HBc positive patients at baseline and 24 weeks after the end of treatment. Post-treatment HBsAg determination was performed in case of HBV-DNA positivity. Serum anti-HBs kinetics was analysed in anti-HBs and anti-HBc positive subjects. RESULTS A cohort of 137 consecutive HCV patients treated with IFN-free regimens in routine clinical practice was evaluated. From this cohort, plasma samples of 44 subjects with positive serology for HBV (anti-HBc positive) were tested for HBV-DNA levels at baseline and 24 weeks after the end of treatment. Two of them were HBsAg-positive, while the others had signs of a past HBV exposure (HBsAg-negative±HBsAb-positive). No reactivation was found in HBcAb-positive and HBsAg-negative subjects. In the two HBsAg-positive, one experienced an increase in HBV-DNA levels of ≥2 log10 IU/mL during treatment. However, the reactivation was without clinical impact and, most important, was followed by HBsAg loss. CONCLUSIONS Based on our experience, a past HBV infection seems not to be a condition predisposing to HBV reactivation. On the contrary, in HBsAg-positive subjects not in suppressive treatment with nucleos(t)ide analogs, regular monitoring of HBV-DNA during and after DAA treatment should be considered.
Annals of Hepatology | 2017
Stefano Gitto; Arrigo F.G. Cicero; E. Loggi; Marina Giovannini; F. Conti; E. Grandini; V. Guarneri; A. Scuteri; Giovanni Vitale; C. Cursaro; Claudio Borghi; Pietro Andreone
INTRODUCTION Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA). MATERIAL AND METHODS We considered patients consecutively treated between January and November 2015 recording clinical data at baseline and week 24 of follow-up. Frozen serum samples were used for apolipoprotein A1 (apoA1), apolipoprotein B (apoB) and lipoprotein (a) [Lp(a)]. Wilcoxon test was utilized to estimate trends and Logistic Regression for predictors of lipid changes. RESULTS We enrolled 100 patients, mostly cirrhotic (81%) and with genotype 1b (59%). Ninety-three patients achieved sustained virological response (SVR), while 7 relapsed. Homeostasis model assessment of insulin resistance declined (from 3 to 2.7, p < 0.001); non-high density lipoprotein (HDL) cholesterol increased from 102 ± 29 to 116 ± 35 (p < 0.001), and Lp(a) from 5.6 ± 6.5 to 9.8 ± 11.5 mg/dL (p < 0.001). Rise of low-density lipoprotein/HDL and apoB/apoA1 ratio were registered (from 1.79 ± 1.10 to 2.08 ± 1.05 and from 0.48 ± 0.18 to 0.53 ± 0.18 mg/dL, p < 0.001). We conducted a subanalysis on patients with relapse. In this subgroup, no change of lipid profile was recorded. At multivariate analysis emerged that the addition of ribavirin to DAA, represented an independent predictor of increased Lp(a) (OR 3.982, 95% CI 1.206-13.144, p = 0.023). CONCLUSION DAA therapy led to reduction of insulin resistance. In contrast, pro-atherogenic lipid changes were observed in patients with SVR. Further studies will be necessary to evaluate the cardiovascular balance between amelioration of glucose metabolism and negative changes of lipid profile.INTRODUCTION Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA). MATERIAL AND METHODS We considered patients consecutively treated between January and November 2015 recording clinical data at baseline and week 24 of follow-up. Frozen serum samples were used for apolipoprotein A1 (apoA1), apolipoprotein B (apoB) and lipoprotein (a) [Lp(a)]. Wilcoxon test was utilized to estimate trends and Logistic Regression for predictors of lipid changes. RESULTS We enrolled 100 patients, mostly cirrhotic (81%) and with genotype 1b (59%). Ninety-three patients achieved sustained virological response (SVR), while 7 relapsed. Homeostasis model assessment of insulin resistance declined (from 3 to 2.7, p < 0.001); non-high density lipoprotein (HDL) cholesterol increased from 102 ± 29 to 116 ± 35 (p < 0.001), and Lp(a) from 5.6 ± 6.5 to 9.8 ± 11.5 mg/dL (p < 0.001). Rise of low-density lipoprotein/HDL and apoB/apoA1 ratio were registered (from 1.79 ± 1.10 to 2.08 ± 1.05 and from 0.48 ± 0.18 to 0.53 ± 0.18 mg/dL, p < 0.001). We conducted a subanalysis on patients with relapse. In this subgroup, no change of lipid profile was recorded. At multivariate analysis emerged that the addition of ribavirin to DAA, represented an independent predictor of increased Lp(a) (OR 3.982, 95% CI 1.206-13.144, p = 0.023). CONCLUSION DAA therapy led to reduction of insulin resistance. In contrast, pro-atherogenic lipid changes were observed in patients with SVR. Further studies will be necessary to evaluate the cardiovascular balance between amelioration of glucose metabolism and negative changes of lipid profile.
Annals of the New York Academy of Sciences | 2010
E. Grandini; F. Cannoletta; A. Scuteri; C. Fortini; E. Loggi; C. Cursaro; A. Riili; R. Di Donato; Annagiulia Gramenzi; Mauro Bernardi; P. Andreone
The current standard therapy for the treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin, although many patients fail to clear the virus and their retreatment options are still unsatisfactory. Thymosin α1 (Tα1) is an immunomodulating agent that has been proposed as complementary therapy for chronic HCV, especially in the setting of difficult‐to‐treat patients. The aim of this study was to evaluate, in patients nonresponsive to previous Peg‐based therapy, the effect of standard antiviral therapy with or without Tα1 on peripheral lymphocyte subsets. Twenty‐four patients, 12 receiving Tα1 and 12 standard therapy, were enrolled. Peripheral subpopulations were analyzed by flow cytometry. Although the addition of Tα1 did not seem to significantly modify the T‐lymphocyte subpopulations, as comparable behaviors were observed in the CD4 and CD8 longitudinal evaluation, Tα1 produced an earlier increase of natural killer cells. An accurate selection of HCV patients who can benefit from immunomodulation is needed.
PLOS ONE | 2017
E. Loggi; Silvia Galli; Giovanni Vitale; Roberto Di Donato; Ranka Vukotic; E. Grandini; Marzia Margotti; V. Guarneri; Giuliano Furlini; Claudio Galli; Maria Carla Re; Pietro Andreone
Aim To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs). Methods Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated. Results A sustained viral response (SVR) was achieved in 82 patients (91%), whereas 11 relapsed (R) and 1 showed a virological breakthrough while receiving treatment. HCV-RNA and HCV-Ag showed good concordance (kappa = 0.62) and correlation. No significant differences between SVR and R was observed in either assay at 2 and 4 weeks after the start of treatment. At 8 weeks, HCV-Ag showed higher accuracy than HCV-RNA (AUC: 0.74 vs. 0.55) and there was a significantly greater decrease from baseline in SVR than in R (4.01 vs. 3.36 log10; p<0.05). Conclusions Monitoring during treatment with DAAs by using either HCV-RNA or HCV-Ag has only a limited predictive value for SVR. Since those assays are equivalent for identifying a virological relapse, HCV-Ag may be preferred from an economical and organizational perspective.
Liver International | 2017
Sirio Fiorino; E. Loggi; Gabriella Verucchi; Donatella Comparcola; Ranka Vukotic; Michele Pavoni; E. Grandini; C. Cursaro; Silvia Maselli; Maria Letizia Bacchi Reggiani; Cristina Puggioli; Lorenzo Badia; Silvia Galli; Pierluigi Viale; Mauro Bernardi; Pietro Andreone
The treatment of chronic hepatitis B infection (CHB) in children is still an area of great uncertainty. Vitamin E is an immunostimulating/antioxidant compound proven to be safe and effective for the treatment of adult CHB. The aim of this phase 2 controlled study was to evaluate the safety and efficacy of vitamin E for the treatment of paediatric HBeAg‐positive CHB.
Journal of Hepatology | 2014
Sirio Fiorino; Gabriella Verucchi; D. Comparcola; M. Pavoni; E. Grandini; E. Loggi; S. Maselli; L. Bacchi-Reggiani; Pierluigi Viale; Mauro Bernardi; P. Andreone
P1087 ENTECAVIR AND TENOFOVIR MONOTHERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER TURKISH STUDY IN CLINICAL PRACTICE R. Idilman, O. Keskin, F. Gunsar, M. Koruk, C.E. Meral, A. Tuzun, M. Gulsen, A.H. Elhan, U.S. Akarca, C. Yurdaydin. Ankara University, School of Medicine, Ankara, Ege University, Izmir, Gaziantep University, Gaziantep, Turkey E-mail: [email protected]
World Journal of Gastroenterology | 2008
Stefania Lorenzini; Stefano Gitto; E. Grandini; Pietro Andreone; Mauro Bernardi
Hepatology International | 2015
Alessia Piluso; Laura Gragnani; Elisa Fognani; E. Grandini; Monica Monti; Cristina Stasi; E. Loggi; Marzia Margotti; F. Conti; Pietro Andreone; Anna Linda Zignego
Journal of Hepatology | 2017
Stefano Gitto; Arrigo F.G. Cicero; E. Loggi; Marina Giovannini; F. Conti; E. Grandini; V. Guarneri; A. Scuteri; Giovanni Vitale; C. Cursaro; Claudio Borghi; Pietro Andreone